NewAmsterdam Pharma Reports Quarterly Results for Quarter Ended June 30, 2026

What Happened
NewAmsterdam Pharma Company N.V. announced corporate updates and reported its financial results for the quarter ended June 30, 2026 via a press release issued and furnished to the SEC on August 5, 2026. The company filed the information on Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: August 5, 2026; reporting period: quarter ended June 30, 2026.
• The press release containing the results and corporate updates is furnished as Exhibit 99.1 to the Form 8-K.
• The 8-K was signed by Ian Somaiya, Chief Financial Officer, on behalf of NewAmsterdam Pharma Company N.V.
• The disclosure was filed under Item 2.02 (results of operations) and Item 9.01 (exhibits).

Why It Matters
This 8-K notifies investors that the company has released its latest quarterly results and corporate updates; investors should review the furnished press release for specific figures (revenue, earnings, guidance) and any material operational developments. Because the Form 8-K furnishes the press release rather than embedding detailed financial statements in the filing itself, investors may also want to watch for the company’s upcoming periodic reports (e.g., 10-Q) for complete financial statements and management discussion.